Traxaranya 50 mg/ml 5 ml, 10 pcs.

Antifibrinolytic agent, is a competitive (at high concentrations – non-competitive) inhibitor of plasminogen activation and its conversion into plasmin. It has local and systemic hemostatic as well as anti-allergic and anti-inflammatory effects by inhibiting the formation of kinins and other active peptides involved in allergic and inflammatory reactions. It has local and systemic hemostatic action in bleeding associated with increased fibrinolysis (platelet pathology, menorrhagia). Tranexamic acid also has anti-allergic and anti-inflammatory effects by inhibiting the formation of kinins and other active peptides involved in allergic and inflammatory reactions.Tranexamic acid at 1 mg/ml does not aggregate platelets in vitro, at concentrations up to 10 mg/ml has no effect on platelet count, clotting time or various clotting factors in whole blood or nitrate blood in healthy humans. On the other hand, granexamic acid at both 1 mg/ml blood and 10 mg/ml blood concentrations prolongs thrombin time.

Indications

Distributed in tissues relatively uniformly (except in cerebrospinal fluid, where the concentration is 1/10 of the plasma concentration). It penetrates the placental barrier (the concentration in umbilical cord blood after administration to a woman at a dose of 10 mg/kg can be quite high, about 30 µg/ml fetal serum) and the blood-brain barrier (BBB). excreted with breast milk (reaching about 1% of the concentration in maternal plasma). Found in seminal fluid, where it reduces fibrinolytic activity, but does not affect sperm migration. Transsamic acid rapidly diffuses into the joint fluid and through the synovial membranes, and is found in the joint fluid at the same concentration as in blood serum. Biological half-life from joint fluid is about 3 hours. Initial distribution volume Vd is 9-12 liters. Binding to plasma proteins (profibrinolysin) is less than 3%.

In the blood about 3% is bound to protein (plasminogen). Total renal clearance is equal to plasma clearance.

The antifibrinolytic concentration in various tissues lasts for 17 hours. in plasma – up to 7-8 hours.

It is metabolized to a small extent. The area under the curve “concentration/time” AUC has a three-phase form with a T1/2 in the terminal phase of 2 hours. Total renal clearance is equal to plasma clearance (7 l/h). It is excreted by the kidneys (the main route is glomerular filtration), more than 95% unchanged during the first 12 hours. After intravenous administration at a dose of 10 mg/kg during 24 hours about 90% of tranexamic acid is eliminated by glomerular filtration. Two metabolites of tranexamic acid have been identified: N-acetylated and deaminated derivatives. There is a risk of cumulation of tranexamic acid in impaired renal function.

Active ingredient

Composition

How to take, the dosage

0.6 mg/kg is administered in the primary filling volume of the artificial circulatory machine (AIC).

In local fibrinolysis, 250-500 mg 2-3 times a day. In prostatectomy or bladder surgeries – 1 g during the operation, and then

1 g every 8 hours for 3 days, then switch to oral dosage form “tablet” until macrohematuria disappears.

If the risk of bleeding is high, with systemic inflammatory reaction syndrome – 10-11 mg/kg 20-30 minutes before the intervention.

Patients with coagulopathies, before tooth extraction are administered at a dose of 10 mg/kg, after tooth extraction switch to oral dosage form “tablet”.

The mode of administration

The tranexamic acid (TK) solution is intended for intravenous administration (intravenous injections and infusions). The recommended rate of administration is 50 mg/min:

– for undiluted TC solution (50 mg/ml), 1 ml/min;

– for diluted to 1% (10 mg/ml) TC solution, 5 ml/min;

– for diluted to 2% (20 mg/ml) TC solution, 2.5 ml/min.

In adult cardiac surgery, the loading dose is administered preoperatively followed by an extended infusion during surgery. The recommended prolonged infusion rate is 4.5 mg/kg of patient body weight per hour. In a 100 kg patient, an undiluted TC solution (50 mg/ml) is administered at 45 ml/h: and diluted to 2% (20 mg/ml) TC is administered at 22.5 ml/h.

The rapid intravenous administration may cause dizziness and/or hypotension (decreased blood pressure).

The following solutions can be used to dilute Traxar, an intravenous solution:

– 0.9% sodium chloride solution

– 5% glucose solution

– dextran 40

– dextran 70

– Ringer’s solution.

The required volume of Traxar. solution for intravenous administration can be added to the selected infusion solution to achieve final concentrations of 1 or 2 g in 100 ml (10 or 20 mg/ml. 1% or 2%). The diluted solution should be used immediately after preparation. If storage of the prepared solution is necessary, it should be stored at 2 – 8°C for no more than 24 hours. Unused solution within 24 hours should be disposed of.

Interaction

Special Instructions

Contraindications

Side effects

Digestive system disorders: anorexia, nausea, vomiting, heartburn, diarrhea.

CNS disorders: dizziness, weakness, somnolence, color perception disorders, blurred vision, seizures (in case of rapid intravenous injection).

Blood coagulation: thrombosis, thromboembolism (risk of development is minimal).

Cardiovascular system: tachycardia, chest pain, arterial hypotension (with rapid intravenous infusion). Allergic reactions: skin rash. itching. urticaria.

Overdose

Similarities